Evicenter
MarkdownMedical informationP&T meetings
Ersodetug (RZ358)

Tumor hyperinsulinism

Manufacturer
Rezolute
Launch
Not announced
Last updated
140 sources

Section 6 of 6

References

140 sources

  1. Afinitor prescribing information (2026) (opens in a new tab)
  2. Ata et al. (2024) (opens in a new tab)
  3. Bernard et al. (2013) (opens in a new tab)
  4. Bodnar et al. (2014) (opens in a new tab)
  5. Boss et al. (2024) (opens in a new tab)
  6. Brown et al. (2018) (opens in a new tab)
  7. Cabometyx prescribing information (2025) (opens in a new tab)
  8. Cahn et al. (2023) (opens in a new tab)
  9. Chida et al. (2024) (opens in a new tab)
  10. Christ et al. (2013) (opens in a new tab)
  11. ClinicalTrials.gov NCT04538989 (opens in a new tab)
  12. ClinicalTrials.gov NCT04538989 results (opens in a new tab)
  13. ClinicalTrials.gov NCT05735912 (opens in a new tab)
  14. ClinicalTrials.gov NCT06208215 (opens in a new tab)
  15. ClinicalTrials.gov NCT06881992 (opens in a new tab)
  16. ClinicalTrials.gov NCT07262970 (opens in a new tab)
  17. Corbin et al. (2014) (opens in a new tab)
  18. Crinò et al. (2023) (opens in a new tab)
  19. Crippa et al. (2012) (opens in a new tab)
  20. Cryer et al. (2009) (opens in a new tab)
  21. Dai et al. (2019) (opens in a new tab)
  22. Dastamani et al. (2024) (opens in a new tab)
  23. de Carbonnières et al. (2021) (opens in a new tab)
  24. Demirbilek et al. (2025) (opens in a new tab)
  25. Dizon et al. (1999) (opens in a new tab)
  26. Dynkevich et al. (2013) (opens in a new tab)
  27. eCQI Resource Center CMS816v5 (2026) (opens in a new tab)
  28. El Sayed et al. (2021) (opens in a new tab)
  29. EMA congenital hyperinsulinism orphan designation (2016) (opens in a new tab)
  30. EMA insulinoma orphan designation (2024) (opens in a new tab)
  31. ENDO Annual Meeting (2026) (opens in a new tab)
  32. EU Clinical Trials Information System 2024-515447-36-00 (opens in a new tab)
  33. FDA Orphan Drug Designations and Approvals (2015) (opens in a new tab)
  34. FDA Orphan Drug Designations and Approvals (2024) (opens in a new tab)
  35. Friebe et al. (2024) (opens in a new tab)
  36. Fukuda et al. (2006) (opens in a new tab)
  37. Gill et al. (1997) (opens in a new tab)
  38. Guerrero-Pérez et al. (2026) (opens in a new tab)
  39. Gvoke prescribing information (2025) (opens in a new tab)
  40. Habibollahi et al. (2020) (opens in a new tab)
  41. Hackeng et al. (2023) (opens in a new tab)
  42. Halfdanarson et al. (2020) (opens in a new tab)
  43. Hendren et al. (2018) (opens in a new tab)
  44. Hirshberg et al. (2000) (opens in a new tab)
  45. Hirshberg et al. (2005) (opens in a new tab)
  46. Hoff and Vassilopoulou-Sellin (1998) (opens in a new tab)
  47. Hofland et al. (2023) (opens in a new tab)
  48. Hofland et al. (2024) (opens in a new tab)
  49. Howarth et al. (2025) (opens in a new tab)
  50. Howe et al. (2020) (opens in a new tab)
  51. Ito et al. (2015) (opens in a new tab)
  52. Ito et al. (2021) (opens in a new tab)
  53. Johnson et al. (2017) (opens in a new tab)
  54. Journal of Clinical Endocrinology and Metabolism insulinoma correction (2026) (opens in a new tab)
  55. Jürgensen et al. (2024) (opens in a new tab)
  56. Karamanolis et al. (2024) (opens in a new tab)
  57. Koch et al. (2025) (opens in a new tab)
  58. Komatsu et al. (2016) (opens in a new tab)
  59. Kulke et al. (2009) (opens in a new tab)
  60. Kurakawa et al. (2021) (opens in a new tab)
  61. Linch et al. (2021) (opens in a new tab)
  62. Lundholm et al. (2025) (opens in a new tab)
  63. Lutathera prescribing information (2024) (opens in a new tab)
  64. Masharani et al. (2025) (opens in a new tab)
  65. NCCN Neuroendocrine and Adrenal Tumors guideline (opens in a new tab)
  66. Niitsu et al. (2019) (opens in a new tab)
  67. Nockel et al. (2018) (opens in a new tab)
  68. Osataphan et al. (2023a) (opens in a new tab)
  69. Osataphan et al. (2023b) (opens in a new tab)
  70. Patel et al. (2018) (opens in a new tab)
  71. Patel et al. (2026) (opens in a new tab)
  72. Patti et al. (2026) (opens in a new tab)
  73. Pattison et al. (2025) (opens in a new tab)
  74. Pavel et al. (2020) (opens in a new tab)
  75. Pediatric Endocrine Society Annual Meeting (2026) (opens in a new tab)
  76. Peltola et al. (2018) (opens in a new tab)
  77. Peltola et al. (2021a) (opens in a new tab)
  78. Peltola et al. (2021b) (opens in a new tab)
  79. Placzkowski et al. (2009) (opens in a new tab)
  80. Proglycem prescribing information (2026) (opens in a new tab)
  81. Rezolute congenital HI breakthrough therapy release (2025) (opens in a new tab)
  82. Rezolute congenital HI FDA meeting release (2026) (opens in a new tab)
  83. Rezolute EAP patient profiles (2026) (opens in a new tab)
  84. Rezolute ENDO presentations release (2026) (opens in a new tab)
  85. Rezolute FDA review update release (2026) (opens in a new tab)
  86. Rezolute first quarter fiscal 2027 results release (2026) (opens in a new tab)
  87. Rezolute for patients page (opens in a new tab)
  88. Rezolute Form 10-K (2026) (opens in a new tab)
  89. Rezolute Form 10-Q (2026) (opens in a new tab)
  90. Rezolute investor event presentation (2025) (opens in a new tab)
  91. Rezolute January corporate presentation (2026) (opens in a new tab)
  92. Rezolute NICTH validation release (2024) (opens in a new tab)
  93. Rezolute October corporate presentation (2026) (opens in a new tab)
  94. Rezolute partial clinical hold release (2024) (opens in a new tab)
  95. Rezolute pre-BLA recommendation release (2026) (opens in a new tab)
  96. Rezolute prospectus supplement (2026) (opens in a new tab)
  97. Rezolute RIZE PES data release (2022) (opens in a new tab)
  98. Rezolute RIZE topline release (2022) (opens in a new tab)
  99. Rezolute second quarter fiscal 2024 results release (2024) (opens in a new tab)
  100. Rezolute September corporate presentation (2025) (opens in a new tab)
  101. Rezolute sunRIZE and EAP insights release (2026) (opens in a new tab)
  102. Rezolute sunRIZE PES presentation release (2026) (opens in a new tab)
  103. Rezolute sunRIZE topline release (2025) (opens in a new tab)
  104. Rezolute third quarter fiscal 2024 results release (2024) (opens in a new tab)
  105. Rezolute tumor HI breakthrough therapy release (2025) (opens in a new tab)
  106. Rezolute tumor HI evidence release (2023) (opens in a new tab)
  107. Rezolute tumor HI IND clearance release (2024) (opens in a new tab)
  108. Rezolute tumor HI orphan drug designation release (2024) (opens in a new tab)
  109. Rezolute upLIFT design alignment release (2025) (opens in a new tab)
  110. Rezolute upLIFT enrollment completion release (2026) (opens in a new tab)
  111. Rezolute upLIFT interim release (2026) (opens in a new tab)
  112. Rezolute upLIFT results release (2026) (opens in a new tab)
  113. Rizzatti et al. (2025) (opens in a new tab)
  114. Ryan et al. (2025) (opens in a new tab)
  115. Sada et al. (2020) (opens in a new tab)
  116. Sada et al. (2021) (opens in a new tab)
  117. Sandostatin LAR Depot prescribing information (2024) (opens in a new tab)
  118. Schubert et al. (2023) (opens in a new tab)
  119. Service et al. (1991) (opens in a new tab)
  120. Signifor prescribing information (2024) (opens in a new tab)
  121. Somatuline Depot prescribing information (2024) (opens in a new tab)
  122. Strosberg et al. (2024) (opens in a new tab)
  123. Strosberg et al. (2026) (opens in a new tab)
  124. Svensson et al. (2022) (opens in a new tab)
  125. Teale and Marks (1998) (opens in a new tab)
  126. Teale and Wark (2004) (opens in a new tab)
  127. Vega-Beyhart et al. (2025) (opens in a new tab)
  128. Veltroni et al. (2020) (opens in a new tab)
  129. Vezzosi et al. (2005) (opens in a new tab)
  130. Vezzosi et al. (2008) (opens in a new tab)
  131. Vu et al. (2024) (opens in a new tab)
  132. WHO INN Proposed List 128 (2022) (opens in a new tab)
  133. Wiese et al. (2023) (opens in a new tab)
  134. XOMA (2014) (opens in a new tab)
  135. XOMA (2015) (opens in a new tab)
  136. XOMA Form 10-K (2015) (opens in a new tab)
  137. XOMA Form 10-K (2016) (opens in a new tab)
  138. XOMA Form 10-Q (2015) (opens in a new tab)
  139. Yamada et al. (2020) (opens in a new tab)
  140. Zandee et al. (2019) (opens in a new tab)